TTrialPathMatch Me to Trials
← Back to trials
RecruitingAdvanced Lung Non-Small Cell CarcinomaMetastatic Lung Non-Small Cell CarcinomaStage IV Lung Cancer AJCC v8

MRX-2843 and Osimertinib for the Treatment of Advanced EGFR Mutant Non-small Cell Lung Cancer

Eligible age

18+ yrs

Accepts

All genders

Locations

1 state

Healthy volunteers

No

See if you qualify for this study

Answer a few quick questions about your location and health. Takes about a minute.

Check my eligibility →

About this study

This phase Ib trial evaluates the best dose and side effects of MRX-2843 when given in combination with osimertinib in treating patients with EGFR gene mutant non-small cell lung cancer that has spread to other places in the body (advanced). MRX-2843 and osimertinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.

Sponsor: Emory University

You may qualify if…

  • ✓ Patients must have histologically confirmed metastatic non-small cell lung cancer (NSCLC) with activating EGFR mutation including typical and atypical mutations in egfr exons 19 and 21
  • ✓ Eastern Cooperative Oncology Group (ECOG) performance status of 0-2
  • ✓ Patients in the expansion cohort must have measurable disease, defined as at least one lesion that can be accurately measured in at least one dimension (longest diameter to be recorded for non-nodal lesions and short axis for nodal lesions) as \>= 20 mm (\>= 2 cm) by chest x-ray or as \>= 10 mm (\>= 1 cm) with computed tomography (CT) scan, magnetic resonance imaging (MRI), or calipers by clinical exam
  • ✓ Ability to safely swallow oral medication
  • ✓ Absolute neutrophil count \>= 1500/mm\^3
  • ✓ Platelet count \>= 100,000/mm\^3
  • ✓ Hemoglobin \>= 8.5 g/dL (must be \> 2 weeks post-red blood cell transfusion)
  • ✓ Bilirubin =\< 1.5 x the upper limit of normal (ULN). For subjects with documented Gilbert's disease, bilirubin =\< 3.0 mg/dL. For subjects with documented liver metastases, bilirubin =\< 2.5 x ULN

You may not qualify if…

  • ✕ Patients who have had chemotherapy or radiotherapy within 4 weeks (6 weeks for nitrosoureas or mitomycin C) prior to entering the study
  • ✕ Patients who have not recovered from adverse events due to prior anti-cancer therapy (i.e., have residual toxicities \> grade 1)
  • ✕ Patients who are receiving any other investigational agents
  • ✕ Patients with symptomatic untreated brain metastases would be excluded from this clinical trial because of their poor prognosis and because they often develop progressive neurologic dysfunction that would confound the evaluation of neurologic and other adverse events. Patient with treated or asymptomatic untreated brain metastasis is allowed on study
  • ✕ History of allergic reactions attributed to compounds of similar chemical or biologic composition to MRX-2843 or osimertinib
  • ✕ Patients with known diagnosis of interstitial lung disease/pneumonitis
  • ✕ Patients with corrected QT (QTc) interval prolongation \> 500 msec (average of 3 readings), family history of congenital long QTc syndrome or torsades
  • ✕ Patients with known cardiomyopathy or decreased left ventricular ejection fraction (LVEF) \< 50%

Where it's recruiting

Georgia

Atlanta

Source: ClinicalTrials.gov · NCT04762199 · last updated 2026-03-31